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  Albumin is the most abundant protein in blood where it has a pivotal role as a transporter of 
fatty acids and drugs. Like IgG, albumin has long serum half-life, protected from degradation by 
pH-dependent recycling mediated by interaction with the neonatal Fc receptor, FcRn. Although 
the FcRn interaction with IgG is well characterized at the atomic level, its interaction with 
albumin is not. Here we present structure-based modelling of the FcRn  –  albumin complex, 
supported by binding analysis of site-speciﬁ  c mutants, providing mechanistic evidence for 
the presence of pH-sensitive ionic networks at the interaction interface. These networks 
involve conserved histidines in both FcRn and albumin domain III. Histidines also contribute 
to intramolecular interactions that stabilize the otherwise ﬂ  exible loops at both the interacting 
surfaces. Molecular details of the FcRn  –  albumin complex may guide the development of novel 
albumin variants with altered serum half-life as carriers of drugs.                
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 A
lbumin is a multifunctional transporter of a range of diff  er-
ent endogenous as well as exogenous compounds, such as 
ions, fatty acids, amino acids, hemin, bilirubin and various 
drugs  1  . It is the most abundant protein in blood and thus contrib-
utes to maintaining the osmotic pressure. Th   e high serum concen-
tration of albumin is due to the rate of synthesis that takes place in 
the liver and its interaction with the neonatal Fc receptor, abbrevi-
ated FcRn  2,3  . FcRn is a dual binding receptor that, in addition to 
albumin, binds IgG, and protects both proteins from intracellu-
lar degradation  3 – 5 .  Th  us, FcRn has a key role in prolonging their 
half-lives. 
  FcRn is a nonclassical major histocompatibility (MHC) class 
I molecule that consists of a unique transmembrane heavy chain 
(HC) that is non-covalently associated with the common   β 2-micro-
globulin (  β  2m). Crystal structures of FcRn show the extracellular 
part of the HC with an amino-terminal   α 1 –  α  2 platform of eight 
antiparallel  β -pleated strands topped by two long  α -helices followed 
by the membrane proximal   α 3-domain  ( Fig.  1a ) 6 – 8 .  Th  e    β 2m  unit 
is tightly bound to residues located below the   α 1 –  α  2 platform and 
to the   α  3-domain. Whereas classical MHC class I molecules bind 
to short peptides in their peptide-binding groove, located between 
the two   α  -helices on the   α 1- α  2 platform, this groove is occluded 
and empty in FcRn  7,8  . Instead, the MHC class I fold of FcRn has 
evolved to bind to IgG and albumin. 
  Both IgG and albumin bind to FcRn in a strictly pH-dependent 
manner, with binding at acidic and no binding or release at neu-
tral pH (refs   2,7,9  ). Th  e model of how the receptor mediates res-
cue from lysosomal degradation has been deduced from imaging 
studies of FcRn  –  IgG traffi   cking in live cells  5,10 – 12 .  In  short,  FcRn, 
predominantly localized in acidic endosomal compartments, 
encounters proteins continuously taken up by fl  uid-phase endo-
cytosis. Th  e low pH in the vesicles allows ligand binding. Subse-
quently, FcRn-ligand complexes are exported to the cell surface, 
where exposure to the higher physiological pH of the bloodstream 
triggers release of the ligands by a so-called kiss-and-run exocy-
totic mechanism  5,10  . Proteins that do not bind to FcRn progress to 
lysosomes for proteolytic degradation. 
 A key role for FcRn in half-life regulation has been demonstrated 
using genetically modifi  ed mice, as mice lacking FcRn have serum 
levels of IgG and albumin that are four to fi  ve and two to three -fold 
lower than normal mice, respectively  2,13 .  Th  e cell types responsi-
ble for FcRn recycling have been revealed using mice conditionally 
deleted for FcRn in endothelial or haematopoietic cells that show 
serum levels of IgG and albumin four and two-fold lower than in 
normal mice, respectively  14  . A human example is familial hyper-
catabolic hypoproteinemia, where defi  ciency in FcRn expression 
results in abnormally low levels of both ligands  15 .  Furthermore, 
variants of HSA with carboxy-terminal truncations have unusual 
low serum levels  16  . In line with this, the so-called HSA  –  Bartin 
variant, known to lack the C-terminal DIII except for the fi  rst 29 
amino acids, shows severely reduced FcRn binding  17,18 . 
  Our molecular understanding of the FcRn  –  IgG interaction has 
been deduced from site-directed mutagenesis, and the atomic-
resolution structure of a complex between rat FcRn and rat IgG2a 
Fc that reveals a key role for a cluster of amino acids in the IgG 
Fc elbow region (Ile-253, His-310 and His-435)  4,5 .  Th  ese  residues 
are highly conserved across species, and the involvement of the 
histidines explains the strict pH dependence of the interaction. His-
tidines are positively charged at pH 6.0, and can interact with the 
negatively charged Glu-115 and Glu-116 in the FcRn HC (  Fig. 1a  ). 
 Although the FcRn – IgG interaction is very well characterized, the 
FcRn interaction with albumin is not. To gain detailed insight, we 
constructed a structural model of the complex between hFcRn and 
HSA based on available crystal structures, and, using site-directed 
mutagenesis, we targeted amino-acid residues in both molecules 
to identify key players. Domain DIII of HSA was confi  rmed as the 
principal binding domain, and a natural HSA variant (Casebrook), 
characterized by a single point mutation in a long loop connecting 
subdomains DIIIa and DIIIb  19  , showed reduced affi   nity for hFcRn. 
We identifi  ed three conserved histidine residues in albumin to be 
crucial for pH-dependent binding, one in each of subdomains DIIIa 
(His-464) and DIIIb (His-535), in addition to one in the aforemen-
tioned loop connecting the two (His-510). In addition, we reveal a 
regulatory role for His-166 in the  α 2-domain of hFcRn in stabilizing 
a fl  exible loop within the   α  1-domain of the receptor that forms an 
ordered structure at acidic pH required for effi   cient HSA binding. 
Th   e structural modelling predicts that this loop binds in a crevice 
on the surface of HSA formed by the loop connecting the DIII sub-
domains and the last C-terminal   α  -helix. In particular, His-510 on 
HSA interacts with Glu-54 on hFcRn, and Glu-505 on HSA with 
His-166 of hFcRn. Extra loops on both molecules contribute to the 
interaction interface, again characterized by histidine-dependent 
pH-sensitive ionic networks. Our data present a network of inter-
actions that gives a molecular basis for the pH-dependence of the 
binding, which is a prerequisite for FcRn-dependent recycling and 
half-life regulation of albumin.   
 Results  
  HSA DIIIb is crucial for pH-dependent binding to hFcRn   .  
    Albumin consists of three homologous domains (DI, DII and DIII), 
each comprising  α -helices stabilized by a complex network of twelve 
cysteine residues forming six disulfi  de bridges  20 .  Th   e three domains 
are linked by loops and form a heart-shaped structure (  Fig. 1b  ). 
To investigate how each individual domain contributes to hFcRn 
binding, several domain variants (DI – DIII, DII – DIII, DI – DII, DIII) 
as well as wild-type (WT) HSA (  Fig. 1c  ) were expressed in yeast 
(  Fig. 1d  ). Th   e binding of each variant to immobilized recombinant 
hFcRn was measured by surface plasmon resonance (SPR). Equal 
amounts of the HSA variants were injected at pH 6.0 and pH 7.4. 
Th   e HSA variant consisting solely of DIII bound hFcRn, whereas 
the variant lacking DIII did not bind to FcRn at all (  Fig. 1e  ). 
Furthermore, the DI  –  DIII variant bound slightly stronger to hFcRn 
than DIII alone (  Table 1  ). DII, on the other hand, did not seem to 
contribute to binding. 
  Each of the three HSA domains has two subdomains, a and b. 
To address the importance of the C-terminal subdomain DIIIb, we 
engineered an HSA variant where this domain was deleted (HSA  –
  DIIIa). Lack of DIIIb completely abolished hFcRn binding (  Fig. 1f  ). 
For comparison, we included a recombinant version of HSA  –  Bartin, 
which lacks DIII except from the fi  rst 29 amino acids  17 .  Th  ese  results 
demonstrate that an intact DIII is crucial for receptor binding.     
  A point mutation alters hFcRn binding in HSA Casebrook   .  
    HSA is normally non-glycosylated, but a few exceptions exist 
because of rare mutations  16  . One such variant (Casebrook) has a 
single nucleotide substitution that changes the coding from Asp to 
Asn at amino-acid residue 494 (ref.     19), localized in the stretch of 
amino acids (residue 490  –  510) that form a long loop connecting 
subdomains DIIIa and DIIIb (  Figs 2a and 3a  ). Th   is point mutation 
introduces a glycosylation motif (  494 Asn-Glu-Th  r  496  ) and attach-
ment of an N-linked oligosaccharide. We studied migration in 
SDS  –  PAGE and hFcRn binding of a number of recombinant HSA 
variants that allowed us to dissect the role of the oligosaccharide 
and individual amino acids at   494 Asn-Glu-Th  r  496 .  Th  e  recombinant 
version of Casebrook (D494N) migrated more slowly than WT 
HSA in SDS  –  PAGE, which refl  ects attachment of oligosaccharides 
(  Fig. 2b  ). Moreover, in six variants, D494A, D494Q, E495Q, E495A, 
T496A and D494N  /  T496A, the glycosylation motif was disrupted, 
and consequently, all of these mutants migrated like their WT 
counterpart (  Fig. 2b  ). 
  All variants were tested for binding to immobilized hFcRn by 
SPR, and distinct binding diff  erences were detected at acidic pH ARTICLE   
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with a hierarchy from strongest to weakest binding as follows; 
WT    >    T496A    >    D494N / T496A    >    D494N    >    E495Q    >    E495A    >    D494A
    >    D494Q ( Fig. 2c – f ;  Table 1 ). Th   e same trend was obtained by ELISA 
(  Supplementary Fig. S1  ). Th   e binding kinetics revealed major dif-
ferences in dissociation rates for most mutants, while recombinant 
Casebrook (D494N) showed a twofold reduced affi   nity resulting 
from both altered association and dissociation constants. Mutation 
of Asp-494 and Glu-495 to a neutral alanine or a glutamine had 
a large eff  ect on receptor binding, whereas mutation of the fl  ank-
ing Th  r-496 had only a small eff  ect. Th  e HSA Casebrook variant 
isolated from a heterozygous individual bound hFcRn similar to its 
recombinant counterpart (  Fig. 2f  ;   Supplementary Fig. S2  ;   Table 1  ). 
 Th  e Casebrook variant is present at a two to three-fold lower 
level than normal HSA in serum of heterozygous individuals  19 . 
To mimic an   in vivo   situation where the Casebrook variant exists in 
the presence of large amounts of WT HSA that competes for FcRn 
binding, we used a competitive SPR-based assay and found that 
the ability of the natural Casebrook variant to compete for recep-
tor binding was reduced by almost 50  %   compared with HSA WT 
(  Fig. 2g  ), a fi  nding that mirrors the twofold reduction in binding 
affi     nity  ( Table  1 ).   
  Structural implications of HSA Casebrook   .   To investigate whether 
the HSA mutants (T496A, D494N  /  T496A, D494N, E495Q, E495A, 
D494A and D494Q) had any major impact on the global structure, 
their secondary structural elements were determined by circular 
dichroism (CD). No major diff  erence from that of WT HSA was 
observed for any of the mutants at either pH 7.4 or pH 6.0 (  Supple-
mentary Fig. S3  ;   Supplementary Table S1  ). 
  Next, we inspected a crystal structure of HSA  20  , and found 
Asp-494 to be involved in an intramolecular network of polar inter-
actions involving amino acids in both DIIIa and DIIIb (  Fig. 2a  ). 
Th  e carboxylic side chain of Asp-494 forms a charged-stabilized 
salt-bridge with Arg-472 as well as hydrogen bonds with both Gln-
417 and Th  r-496. N-linked glycosylation of Asn-494 will reduce 
its hydrogen-bonding capacity and eliminate the negative compo-
nent of the salt-bridge, which may be important for stabilizing the 
loop. In support of this is the fi  nding that a Q417A mutation also 
shows twofold reduced binding affi   nity for hFcRn (  Fig. 2h  ;   Table 1  ). 
Furthermore, glycosylation, that is, an introduction of a bulky moi-
ety, may destabilize the N-terminal end of the loop encompassing 
residues  490 – 495,  and  thus  aff  ect its conformation and ability to 
interact with hFcRn. 
  Besides Asp-494, Glu-495 and Th   r-496 at the N-terminal end of 
the loop, we targeted two charged residues (Lys-500 and Glu-501) in 
addition to Pro-499 in the middle of the loop (  Fig. 3a  ) by mutagen-
esis and investigated the eff  ect on hFcRn binding. We found mod-
erate eff  ects of P499A and E501A, while mutation of the positively 
charged Lys-500 dramatically reduced binding to the receptor by 
more  than  30-fold  ( Fig.  3b ;   Table  1 ).   
  Crucial roles of conserved histidines in HSA DIII   .    Guided  by 
the fact that histidine residues are key players in the strictly pH-
dependent  IgG – FcRn  interaction 4,5  , we assessed the role of the four 
histidines found within HSA DIII. Of these, three are highly con-
served across species (His-464, His-510 and His-535) and one is not 
(His-440) (  Supplementary Table S2  ). Whereas His-440 and His-464 
are found within DIIIa, His-510 is localized to the end of the loop 
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connecting DIIIa and DIIIb, and His-535 is found in one of the   α -
helices of DIIIb (  Fig. 3a  ). All four histidines were mutated individu-
ally to glutamine, and the corresponding mutants were expressed in 
yeast (  Supplementary Fig. S4  ) before they were tested for binding 
to hFcRn at pH 6.0. Mutation of each of the three conserved histi-
dines almost completely abolished binding, whereas mutation of the 
non-conserved His-440 did not (  Fig. 3c  ;   Table 1  ). Th   us, we pinpoint 
these three histidines within DIII as fundamental for pH-dependent 
hFcRn binding, which parallels the requirement for histidines in the 
Fc region of IgG (His-310 and His-435)  4,5 . 
  Furthermore, alanine substitutions of two positively charged 
lysines (Lys-536 and Lys-538) and Pro-537 in the vicinity of His-535 
were also shown to moderately attenuate binding to hFcRn (  Fig 3d  ; 
  Table 1  ). Taken together, the binding data defi  ne a core structural 
area on DIII important for pH-dependent hFcRn binding.     
  Mapping the HSA binding site on hFcRn   .     We   h a v e   p r e v i o u s l y  
identifi   ed a highly conserved histidine residue localized to the 
  α  2-domain of both mouse and human FcRn HC to be crucial 
for albumin binding (His-168 and His-166, respectively)  21,22 . 
To obtain a molecular explanation, we inspected a crystal structure 
of hFcRn that was recently solved under acidic conditions (pH 4.2) 
( Fig.  1a ) 23  . We found that His-166 is engaged in a network of 
intramolecular interactions that involves charge-stabilized hydro-
gen bonds with Glu-54 and Tyr-60 found on a surface-exposed loop 
within the  α 1-domain (residue 51 – 60) ( Fig. 4a ). At low pH, His-166 
will carry a positive charge, and we propose that uncharged His-
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           Table  1       |     SPR-derived  kinetics  for  binding  of  HSA  variants  to 
hFcRn. 
    Albumin 
variant  
   k  a   (10   3     per  Ms)
  
   k  d   (10       −     3      per  s)
  
   k  D  
(  μ M)     a      
   k  D  
(  μ M)     b      
   WT   5.9    ±    0 .1    7. 0     ±    0.2   1.1   2.4 
   DIII   2.6    ±    0 . 0    7 2 . 0     ±    0 . 0    2 7. 6    1 7.4  
   DI – DII   ND  c     ND   ND   ND 
   DII – DIII   1.4    ±    0 . 2    3 0 . 0     ±    0.2   21.4   22.3 
   DI – DIII   3.2    ±    0.1   45.2    ±    0.1   14.1   15.0 
   Q417A   5.0    ±    0.0   11.1    ±    0.1   2.2   3.3 
   H440Q   5.1    ±    0 . 0    7. 0     ±    0.1   1.3   2.5 
   H464Q   NA  d     NA   NA   14.1 
   D494N 
(Casebrook) 
 3.8    ±    0.0   8.5    ±    0.0   2.2   4.6 
   D494A   5.9    ±    0.1   21.0    ±    0.0   3.6   4.2 
   D494Q   5.4    ±    0.2   25.5    ±    0.1   4.7   5.3 
   E495Q   4.2    ±    0.0   13.1    ±    0.0   3.1   3.2 
   E495A   3.8    ±    0.1   13.0    ±    0.0   3.4   3.1 
   T496A   5.4    ±    0 . 0    7. 6     ±    0.2   1.4   2.5 
   D494N / T496A   5.4    ±    0.1   8.5    ±    0.2   1.5   2.5 
   Casebrook   3.6    ±    0 .1    9. 7     ±    0.1   2.7   3.8 
   P499A   2.6    ±    0.0   12.1    ±    0.0   4.6   3.9 
   K500A   14.3    ±    0.2   47.8    ±    0.0   33.4   25.0 
   E501A   5.1    ±    0 . 0    9. 8     ±    0.0   1.9   2.6 
   H510Q   NA   NA   NA   12.1 
   H535Q   NA   NA   NA   16.2 
   K536A   4.4    ±    0 . 2    9. 3     ±    0.1   2.1   3.7 
   P537A   3.7    ±    0.1   14.3    ±    0.2   3.9   5.5 
   K538A   3.9    ±    0 . 0    7.1     ±    0.0   1.8   2.9 
   HSA  568Stop   NA   NA   NA   17.0 
   HSA  DIIIa   ND   ND   ND   ND 
   a        The kinetic rate constants were obtained using a simple ﬁ  rst-order (1:1) Langmuir bimolecular 
interaction model, which assumes that one HSA molecule binds one FcRn. The kinetic values 
represent the average of triplicates.     
   b    The  steady-state  afﬁ  nity constant was obtained using an equilibrium (Req) binding model 
supplied by the BIAevaluation 4.1 software. The afﬁ  nities derived from equilibrium binding data 
represent the average of triplicates.     
   c        ND, not determined because of no or very weak binding.     
   d        NA, not acquired because of fast binding kinetics.     ARTICLE   
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166 will lose its interactions with Glu-54 and Tyr-60 at physiologi-
cal pH, which will result in a more fl  exible loop. Th  is  explanation 
is supported by the fact that this loop region is structurally disor-
dered in the crystal structure of hFcRn solved at basic pH (pH 8.5) 
(  Fig. 4b  ). Further, the corresponding loop is also ordered with a 
defi  ned conformation in the rat FcRn  –  IgG2a Fc co-crystal struc-
ture solved at acidic pH (ref.     6). A comparison of the two hFcRn 
structures at low and high pH suggests a pivotal regulatory role of 
His-166 in locking and release of the fl  exible loop between Trp-51 
and Tyr-60 (  Fig. 4a,b  ). 
  Glu-54 is also involved in an interaction with Gln-56 in the crys-
tal structure of hFcRn (  Fig. 4a  ). To address the importance of these 
residues in loop stabilization and HSA binding, both were individu-
ally mutated to glutamine or alanine, respectively, and the resulting 
receptor variants (hFcRn E54Q and hFcRn Q56A) were tested for 
binding to HSA by ELISA at pH 6.0. Th   e impact of E54Q was strik-
ing, as almost no receptor binding to HSA was detected, whereas 
Q56A partially lost binding to HSA ( Fig. 4c ). Th   us, our data demon-
strate that His-166 stabilizes the   α  1-domain loop of hFcRn in a pH-
dependent fashion through binding to Glu54, and that an ordered 
structure of this loop at acidic pH is indispensable for effi   cient HSA 
binding.   
  A proposed mode of binding   .    On  the  basis  of  the  binding  stud-
ies, we used the ZDOCK algorithm to create a structural model 
of the hFcRn  –  HSA complex using two diff  erent crystal structures 
of hFcRn; the 2.7        Å   resolution structure solved at pH 8.2 and the 
2.6       Å   resolution structure solved at pH 4.2 (refs     8, 23). Th  e  program 
was run with bias towards docking solutions involving His-161 and 
His-166 in hFcRn and the residues His-464, His-510 and His-535 
in HSA in the protein  –  protein interface  20 .  Th  e soft  ware returned 
one model for the docking of DIII against hFcRn with an ordered 
loop at pH 4.2 and eight models for hFcRn at pH 8.2, lacking loop 
residues 52 – 59. Of these eight models, fi  ve evidently showed incom-
patible poses as judged by the position of HSA DI and DII, and were 
rejected. Th   e three remaining models were closely related and had 
the same general structural pose. Superimposing of the low pH 
form of hFcRn on these then showed that the structured loop made 
no severe confl  icts with the docked HSA. 
 Th  e fi  nal selected model reveals interaction areas that fi  t very 
well with the obtained binding data (  Fig. 5a  ). Particularly, the long 
loop between subdomains DIIIa and DIIIb (490  –  510) as well as 
the last C-terminal   α  -helix of HSA form a crevice on the surface 
of HSA into which the pH-dependent and fl  exible loop in hFcRn 
(residues 51  –  60) may bind (  Fig. 5b  ). Th   e structure of hFcRn shows 
that His-166 stabilizes this loop through an intramolecular interac-
tion with Glu-54 (  Fig. 4a  ); however, the model suggests that His-
166 may additionally be engaged in binding to Glu-505 of HSA 
(  Fig. 5b  ). Glu-505 may also interact with Arg-162 of the receptor. 
A key role of His-510 is supported by the fact that it is predicted 
to interact with Glu-54 within the pH-dependent   α 1-domain 
loop (  Fig. 5b  ). Mutation of His-510 (H510Q) reduced binding by 
14-fold  ( Fig.  3c ;   Table  1 ).  Th   us, His-166 in hFcRn and His-510 in 
HSA seem to be involved in regulating an ionic network in the core 
of the hFcRn  –  HSA interaction interface. 
  Furthermore, the predicted involvement of the C-terminal 
  α  -helix of HSA is supported by the fi  nding that deletion of the 
last 17 amino acids of DIIIb (568Stop) reduced binding affi   nity to 
hFcRn by more than 17-fold (  Supplementary Fig. 5  ;   Table 1  ). Th  e 
model also predicts salt-bridges between Lys-150 and Glu-151 in 
hFcRn on one hand and Glu-501 and Lys-500 in HSA ( Fig. 5b ). Th  is 
is in line with the binding data that show reduced binding capacity 
of HSA variants mutated at these positions (  Fig. 3b  ). 
 Another cleft   on the surface of HSA is formed between the DIIIa –
  DIIIb connecting loop and one of the other   α  -helices of DIIIb (resi-
dues 520 – 535). Here His-161 of hFcRn may interact with Glu-531 at 
acidic pH (  Fig. 5b  ). Th   is is in agreement with our previous fi  nding 
where a tenfold reduced binding affi   nity was found when His-161 
was mutated  22 .  Th   e complex could be further reinforced by a salt-
bridge formed between Glu-168 of hFcRn and Lys-524 of DIII, a 
prediction that is supported by the fact that mutation of Glu-168 
moderately reduces binding to HSA (  Supplementary Fig. 6  ). 
  Moreover, His-535 may interact favourably with Phe-157 while 
His-464 is localized close to a   β  -hairpin within hFcRn encompass-
ing residues 99  –  102 that is wedged in-between DI and DIIIa in 
HSA (  Fig. 5c  ). Here hFcRn Asp-101 has several possible partners 
in DI such as Arg-197 and Lys-190, however, they must necessar-
ily undergo some conformational changes in order to get close to 
Asp-101. Interestingly, this   β  -hairpin has two diff  erent conforma-
tions in the low and high pH-forms of hFcRn  8,23  , suggesting that 
Asp-101 is indeed located in a fl  exible element of hFcRn.       
 Discussion 
 FcRn has evolved to protect IgG and albumin from catabolism  5,18,22 . 
Although FcRn binding to IgG has been studied in great detail for 
decades, its recently discovered interaction with albumin is poorly 
understood at the molecular level. In the present study, we provide 
mechanistic evidence for the importance of several interaction 
interfaces on both molecules, revealing how FcRn and HSA interact 
in a pH-sensitive fashion that facilitates cellular recycling. 
 Our  fi  nding that DIII alone, unlike DI-DII, could bind to the 
receptor, modulated by pH, conclusively shows that DIII harbours 
the principal core-binding site for FcRn, as in agreement with pre-
vious reports  9,17  . However, we also show that binding to DIII alone 
is considerably weaker than that for full-length HSA, a fi  nding that 
suggests that there may be a moderate contribution to receptor 
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C-terminal   α  -helix is highlighted in yellow. Representative SPR 
sensorgrams showing binding of immobilized hFcRn to 1       μ  M of WT HSA 
and (  b  ) P499A, K500A and E501A, and (  c  ) H440Q, H464Q, H510Q and 
H535Q as well as (  d  ) K536A, P537A and K538A at acidic pH (6.0).   ARTICLE
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binding from DI or DII, either directly or indirectly. Furthermore, 
a DI  –  DIII construct-bound hFcRn slightly stronger than DIII. One 
may speculate that this is due to structural stabilization of DIII or 
that DI interacts with hFcRn when fused to DIII, although DI in the 
DI  –  DIII fusion has a diff  erent location than DI in WT HSA. Inter-
estingly, the model suggests that there may be a minor interaction 
between DI and hFcRn. 
  Several naturally occurring HSA variants, with mutations in 
DIII, have altered blood levels  16  . One such variant, Casebrook, 
with a point mutation that introduces an N-linked oligosaccharide 
attachment site, constitutes about 35  %   of total HSA in heterozygous 
carriers  19  . Introduction of the mutation in rabbit albumin resulted 
in a 50  %   reduction in half-life when injected into rabbits  24  . On the 
basis of these observations, we engineered an HSA variant mimick-
ing Casebrook and found that it had a twofold reduced affi   nity for 
hFcRn. Th   is was indeed also the case for Casebrook isolated from a 
heterozygous individual. 
  When inspecting the crystal structure of hFcRn solved at acidic 
pH, we found the partially exposed and protonated His-166 to 
be engaged in stabilizing a loop that was disordered at basic pH, 
through binding to an acidic (Glu-54) and a polar (Tyr-60) amino 
acid. Th   e disorder of the loop is likely explained by loss of protona-
tion of His-166 at basic pH, which then regulates the fl  exibility and 
conformation of the loop in a pH-dependent manner. 
  Four histidine residues in HSA DIII were individually mutated 
to glutamines, and three highly conserved histidines (His-464, 
His-510 and His-535;   Supplementary Table S2  ) were found to be 
important for binding at acidic pH. Th   is fact as well as the prereq-
uisite for hFcRn His-166 for binding to HSA, were used to guide 
the hFcRn  –  HSA models output by the docking algorithm. Th  e  best 
model reveals that DIII forms the major interaction interface with 
a possible minor contribution from DI. Furthermore, IgG and HSA 
bind to hFcRn to non-overlapping sites without interfering with 
binding of each other  9,21 , a fact that fi  ts well with the docking model 
where no hindrance exists for simultaneous binding ( Supplementary 
Fig. S7  ). Whether or not HSA binding induces conformation 
changes in the receptor or vice versa cannot be excluded. 
  Following inspection of the docking model, no direct contact 
was found between hFcRn and the oligosaccharide attachment site 
(Asn-494) present in HSA Casebrook. However, Asp-494 is part of 
an extended loop (490  –  510) connecting DIIIa and DIIIb, and it is 
very likely that alteration of the composition at the N-terminal end 
of the loop induces conformation changes in the loop at large. Th  e 
structural importance of Asp-494 and Glu-495 is supported by the 
fact that both residues are highly conserved across species (  Sup-
plementary Table S2  ). Notably, the structural model suggests that 
several residues in the C-terminal end of the loop are in direct con-
tact with the   α 1 –  α  2-platform of the receptor, with predicted key 
residues being His-510 and Glu-505 in HSA, as well as Glu-54 in 
hFcRn. 
  Of the remaining two conserved histidines on DIII, His-535 may 
reinforce the HSA  –  hFcRn complex by aromatic stacking or stabi-
lization of this important loop. His-464, on the other hand, may 
interact, directly or indirectly, with a fl  exible   β  -hairpin element in 
hFcRn. Interestingly, this   β  -hairpin loop is the most fl  exible part of 
hFcRn, except for the pH-dependent loop stabilized by His-166, as 
judged by a comparison of low and high pH crystal structures. Th  e 
fl  exible   β  -hairpin is in contact with both the   α  -helix in HSA that 
contains His-464 as well as a long loop in DI, suggesting an indirect 
conformational   ‘ tuning ’   of  the  hFcRn – HSA  interface  involving  DI 
and DIIIa. Our data support a study showing that mutation of the 
conserved histidines to alanine resulted in increased clearance of 
HSA DIII fused to antibody fragments when injected into mice  25 . 
 Th  e principal function of albumin is to transport fatty acids 
that are bound asymmetrically to hydrophobic pockets within or 
between the three domains  1,26,27  . DIII harbours two high affi   nity 
binding sites, and the fatty acids bind close to the loop between 
DIIIa and DIIIb, which also includes several residues found to aff  ect 
hFcRn binding. Comparison of the fatty acid bound and free states 
of HSA  20,27  , shows no substantial rearrangements within DIII, but 
a considerable shift   in orientation of DI relative to DIII (  Supple-
mentary Fig. S8  ). In eff  ect, superimposing DIII in the fatty acid 
binding HSA onto the corresponding domain in our structural 
model reveals that DI may move away from hFcRn when binding 
to fatty acids. 
 Th  e half-life regulatory function of FcRn may be utilized for 
therapy, as discussed elsewhere  28,29  . Obviously, drugs may fail to 
show convincing eff  ects   in vivo   if their half-lives are short as a con-
sequence of their size being below the renal clearance threshold  30,31 . 
Th   is limits transition from lead candidate to drugs on the market. 
A solution may be genetic fusion of the therapeutics to albumin or 
the IgG Fc, which have shown to improve biodistribution and phar-
macokinetics  29 . 
 Th   e serum half-life of IgG may also be altered, as demonstrated 
for engineered IgGs with mutations in their IgG1 Fc that result in 
improved pH-dependent FcRn binding, and consequently extended 
half-life   in vivo  4,5,32  . No examples have so far been presented for 
albumin, except for the observation that mouse albumin binds more 
strongly to hFcRn than HSA  21 .  Th   e structural hFcRn  –  HSA model 
presented in this study may guide the development of HSA variants 
with altered half-life, which could be attractive for delivery of both 
chemical and biological drugs. 
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(  a  ) At low pH (4.2), the positively charged His-166 forms charge-stabilized hydrogen-bond interactions with Glu-54 and Tyr-60 within the surface-
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  Tumours and infl   amed tissues show increased accumulation 
of albumin as a result of leaky capillaries and defective lymphatic 
drainage  33  . Consequently, albumin-based therapeutics or diagnos-
tics accumulate at the site of tumour or infl  ammation. Because of 
tissue toxicity of the fused molecules, fi  ne-tuning of albumin half-
life may be an attractive approach to improve tumour targeting and 
imaging, as previously shown for IgGs with attenuated affi   nity for 
FcRn  34,35 .  Th   e HSA variants described in this paper, with substan-
tially reduced or intermediate FcRn binding affi   nities, may serve as 
attractive  candidates.   
 Methods  
  Production of hFcRn variants   .    Production  of  hFcRn  has  previously  been 
described  36  .   Gene-segments encoding mutant hFcRn variants (E54Q, Q56A and 
E168A)   were ordered from   Genscript  , subcloned and produced as described  36 .   
  Production of HSA variants   .      Escherichia coli   DH5a 37   was used for manipulation, 
propagation and preparation of HSA DNA. Expression cassettes (  Not I  cassettes) 
contain the   Saccharomyces cerevisiae PRB1   promoter, a leader sequence (MKWVS-
FISLLFLFSSAYSRSLDKR (FL) fused in-frame with the HSA gene (  ALB )  and  the 
  S. cerevisiae ADH1   terminator sequence. Plasmids were generated using standard 
cloning techniques (  Supplementary Table S3  ) or a mixture of this and gap-repair 
in   S. cerevisiae   (  Supplementary Table S4  ). DNAs containing mutations within the 
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the loop corresponding to residues 490  –  510 between subdomains DIIIa and DIIIb form a crevice on the HSA surface into which the pH-dependent and 
ﬂ  exible loop in hFcRn (residues 51  –  59) might bind. His-166 of hFcRn may form strong, charge-stabilized interactions with HSA residues Glu-54 and 
Glu-505. HSA Glu-505 could further interact with hFcRn Arg-162. Possible salt-bridges are formed between Lys-150 and Glu-151 of hFcRn with Glu-501 
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HSA Lys-524. (  c  ) Interaction interface between hFcRn (green surface) and HSA (pink, blue and cyan cartoon) in the docking model. A   β -hairpin  loop 
in hFcRn is wedged in-between domains DI (pink) and DIIIa (cyan) in HSA. The hFcRn Asp-110 could be a partner to either Lys-190 or Arg-197 of HSA 
following some structural rearrangements in this interface. The conserved His-464 is located in the DIIIa   α  -helix contacting the   β -hairpin  loop.  ARTICLE
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  ALB   gene (  GeneArt     GmbH or DNA2.0  ) were subcloned into   Nco I /  Sac I-digested 
pDB2243 (a derivative of pAYE316 (ref.     38) to create plasmids pDB3876  –  pDB3882 
(  Supplementary Table S3  ). Expression cassettes (  Not  I fragments) were obtained 
from pDB3876  –  pDB3886 and ligated into   Not  I-digested pSAC35 (ref.     39 to 
generate pDB3887  –  pDB3893 (  Supplementary Table S3  ). 
  Plasmids used for gap-repair were generated by digesting pDB2244 (containing 
  Not  I cassette from pDB2243 in   Not  I-digested pSAC35) with   Swa  I and the 9.545     kb 
fragment (containing the   S. cerevisiae LEU  2 gene, and the HSA   Not  I cassette) was 
ligated to produce pDB3927. Expression cassettes were generated using DNA frag-
ments (  Nco I /  Bsu36 I,   Avr II /  Sph I  or   Sac I /  Sph  ) containing mutations, subcloned into 
  Nco I /  Bsu36 I,   Avr II /  Sph I  or   Sac I /  Sph  -digested pDB3927 (  Supplementary Table S4  ), 
and then generated in   S. cerevisae   by gap repair. 
  A truncated HSA variant (residues 1-567) was generated by PCR and gap-
repair using the oligonucleotides xAP314 and xAP307 (5  ′ -CTCAAGAAACCTAGG
AAAAGTGGGCAGC-3  ′   and  5 ′ -GAATTAAGCTTATTATAAGCCTAAGGCAG
CTTGACTTGCAGCAACAAGTTTTTTACCCTCCTCGGCTTAGCAGG-3  ′ )  and 
  Phusion Polymerase   (  New England Biolabs  ), to amplify a 493     bp fragment from 
pDB3927. A stop codon was engineered into xAP307 so that translation terminated 
following a.a. 567. Th   e fragment was digested with   Avr II /  Bsu  36I and subcloned 
into   Avr II /  Bsu  36I-digested pDB3927 to produce pDB4557, which was used for 
gap-repair experiments. 
  Plasmids and   S. cerevisiae   strains expressing HSA DI  –  DII (residues 1  –  387) and 
DII – DIII  (residues  183 – 585)  are  described 40 .  Th   e plasmid for DI  –  DIII (residues 
1  –  194 and 381  –  585, respectively) was generated using PCR and gap-repair in 
  S. cerevisiae  . Two DNA fragments were amplifi  ed by PCR from pDB2244 using 
oligonucleotide pairs xAP032  /  xAP058 (5  ′ -ATGTCTGCCCCTAAGAAGATCGTC-
3  ′   and 5  ′ -GTTTGATTAAATTCTGAGGCTCTTCCACGGCAGACGAAGCCTTC
CCTTCATC-3  ′  ) and xAP059  /  xAP033 (5  ′ -GTGGAAGAGCCTCAGAATTTAAT
CAAAC-3  ′   and (5  ′ -GTGGAAGAGCCTCAGAATTTAATCAAAC-3 ′ ).  PCR 
fragments were purifi   ed  using  a   Qiagen    PCR  Purifi  cation kit   before being used 
with   Acc 65I /  Bam  HI-digested pDB3936 to co-transform   S. cerevisiae . 
  A plasmid encoding HSA DIII (residues 381  –  585) (pDB3855) was gener-
ated using a   BfrI  /  HindIII fragment (containing 3  ′   region of the PRB1 promoter 
and DNA encoding the S. cerevisiae leader sequence and DIII)   (  GeneArt  ) ligated 
into   Bfr I /  Hind  III pDB2923 (ref.     41) to create pDB3827. Th   e HSA DIII cassette 
was obtained as a   Not  I fragment from pDB3827 and then ligated into pSAC35 to 
produce pDB3855, which was used to transform   S. cerevisiae .   
  Production of HSA variants in   Saccharomyces cerevisiae     .     Th  e  plasmids 
pDB3887  –  pDB3893 (  Supplementary Table S4  ) were used to transform   S. cerevisiae  
D638cir  0   ( pmt  1 mutant derived of DYB7 (ref.     42)), as described in ref.     43. Transforma-
tion of D638cir  0   by gap-repair was done by digesting the plasmids with   Bst EII /  Bsr BI 
before each digest was purifi  ed using the   Qiagen     PCR Purifi  cation kit  . 100     ng of each 
  Bst EII /  Bsr  BI-digested pDB3927 derivative was mixed with 100     ng   Acc 65I /  Bam HI 
pDB3936 before being used to transform D638cir  0   as described in ref.     43. 
  10     ml BMMD medium (2  %   w  /  v glucose) was inoculated with yeast and grown 
for 48     h at 30       °  C with shaking at 200     r.p.m. 4     ml of each culture was used to inocu-
late  2 × 200   ml  BMMD  media 43  , and grown for 120     h at 30  °  C with shaking at 200     r.
p.m.. Cells were collected by fi  ltration through 0.2-  μ m   vacuum  fi  lter membranes   
(  Millipore  ), and the supernatant retained was concentrated using a   Pall Filtron     LV 
system   fi  tted with an Omega 10     kDa fi  lter (  LV Centramate cassette  ,   Pall Filtron  ). 
  HSA variants were purifi  ed using the   AlbuPure matrix   (  ProMetic BioSciences  ) 
where supernatants were applied to packed bed pre-equilibrated with 50     mM 
sodium acetate pH 5.3, washed with 10 column volume (CV) of equilibration 
buff  er followed by 50     mM ammonium acetate pH 8.0 (10 CV). Protein was eluted 
with 50     mM ammonium acetate, 10     mM octanoate pH 8.0, 50     mM ammonium 
acetate, 30     mM sodium octanoate pH 8.0 or 200     mM potassium thiocyanate. Eluted 
fractions were concentrated and fi  ltered against 10 CV of 50     mM NaCl using 
 Vivaspin20  10   kDa  PES   ( Sartorius ).  HSA  variants  were  quantifi  ed by GP  –  HPLC 
using a   TSK G3000SWXL column   (  Tosoh Bioscience  ). 
  Samples were chromatographed in 25     mM sodium phosphate, 100     mM sodium 
sulphate, 0.05  %   (w  /  v) sodium azide, pH 7.0 at 1     ml     min      −     1 ,  and  quantifi  ed by UV 
detection at 280     nm, relative to a HSA standard. Proteins were analysed using 
precast NuPAGE 4  –  12  %   Bis-Tris gels run with   MOPS SDS buff   er   ( Invitrogen ). 
Samples  (1    μ  g) were diluted 1:1 with reducing sample buff  er (NuPAGE LDS sample 
buff  er) and heated to 70       °  C for 5     min. Electrophoresis was performed for 50     min at 
200     V, and gels were stained with   InstantBlue protein stain   (  Expedeon  ).     
  Construction of GST-tagged HSA variants   .    A  HSA  variant  lacking  subdomain 
DIIIb (HSA  –  DIIIa; residues 1  –  513) was constructed by amplifying a fragment us-
ing oligonucleotide pairs HSA_Forw (5  ′ -TAAGAATTCACCATGAAGTGGGTA
ACCTTTATTTCC-3  ′ )  and  HSA_Rev 513   (5 ′ -AATACTCGAGTATATCTGCATGG
AAGGT-3  ′  ) and the vector pcDNA3-HSA  WT  – GST – oriP,  previously  described 17 . 
Th   e DNA fragment with fl  anking restriction sites (  EcoR I /  Xho  I) was ligated into 
pcDNA – GST – oriP  in-frame  of  a  DNA  encoding  glutathione- S -transferase  (GST) 
from   Schistosoma japonicum   (pcDNA3 – HSA DIIIa  – GST – oriP).  GST-tagged  WT 
HSA, HSA  –  DIIIa and HSA  –  Bartin were produced as previously reported  17 .   
  Isolation of HSA Casebrook   .    Citrate  anti-coagulated  plasma  was  dialysed  against 
16     mM sodium acetate buff  er (pH 5.2) and applied to a 2.6     cm  ×  15     cm column of 
DEAE Sephadex A50 equilibrated in the same buff  er. Bound HSA was eluted with 
600     ml of this buff  er using a pH gradient (5.2  –  4.4) at a fl  ow rate of 1     ml     min      −     1 .  Th  e 
total HSA eluted as a single peak where the leading and trailing third of the peak 
were pooled separately, then concentrated, dialysed and freeze-dried. Analysis on 
SDS  –  PAGE showed these were   ~  95  %   pure WT and HSA Casebrook, respectively.     
  ELISA   .     Microtiter  wells   ( Nunc )  were  coated  with  100    μ  l of titrated amounts of HSA 
variants  (0.7 – 100    μ g   ml     −     1  ), incubated overnight at 4       °  C, and washed 3 times with 
PBS  /  0.005  %   Tween 20 (PBS  /  T), pH 6.0. Wells were then blocked with 4  %     skimmed 
milk   (  Acumedia  ) for 1     h at room temperature (RT) and washed as above. GST-tagged 
hFcRn (0.5       μ g   ml     −     1  ) diluted in PBS  /  T pH 6.0  /  4  %   skimmed milk was added for 1     h 
at RT before washing as above. Bound receptor was detected using a   horseradish 
peroxidase-conjugated goat anti-GST antibody   (  GE Healthcare  ), added for 1     h at RT 
followed by washing with PBS  /  T pH 6.0, and then visualized using   tetramethylbenzi-
dine  substrate   ( Calbiochem ).  Th   e coating levels of HSA variants were controlled using a 
  horseradish peroxidase-conjugated anti-HSA antibody   (  Abcam  ). Binding of 1       μ g   ml     −     1  
of HSA WT-GST, HSA  –  DIIIA  –  GST and HSA  –  Bartin was measured using hFcRn 
(2    μ l   ml     −     1  ) coated in wells following by washing and detection as described above.     
  SPR   .    A   Biacore  3000  instrument   ( GE  Healthcare )  was  used  with  CM5  sensor  chips 
coupled with hFcRn  –  GST (  ~  1,000  –  2,000 RU) using amine coupling chemistry 
as described by the manufacturer. Th   e coupling was performed by injecting 
10 – 12    μ g   ml     −     1   of each protein into 10     mM   sodium acetate, pH 4.5   (  GE Health-
care ).  Phosphate  buff  er (67     mM phosphate buff  er, 0.15     M NaCl, 0.005  %   Tween 20) 
at pH 6.0 or 7.4, or HBS-P buff  er (0.01     M HEPES, 0.15     M NaCl, 0.005  %   surfactant 
P20) at pH 7.4 were used as running buff  er and dilution buff  er. Kinetic measure-
ments were performed by injecting serial dilutions of HSA variants (80  –  0.1       μ M) 
at  25    ° C  with  50    μ l   min     −     1  . All data were zero adjusted, and the reference cell value 
was subtracted. Kinetics were calculated using the Langmuir 1:1 ligand model and 
steady-state affi   nity model provided by the BIAevaluation 4.1 soft  ware. Competi-
tive binding was measured by injecting hFcRn (100     nM) alone or together with 
HSA  variants  (0.015 – 1,000   nM)  over  immobilized  HSA  ( ~ 2,000 – 2,500  RU).   
  CD spectroscopy      .     CD spectra were recorded using a   Jasco J-810 spectropolarim-
eter   (  Jasco International  ) calibrated with   ammonium d-camphor-10-sulfonate   
(  Icatayama Chemicals  ). Measurements were performed with HSA (2     mg     ml      −     1 ) 
in 10     mM PBS (pH 6.0) without NaCl added, at 23       °  C using a   quartz cuvette   
(  Starna  ) with a path length of 0.1     cm. Each sample was scanned 7 times at 
20   nm   min     −     1   (bandwidth of 1     nm, response time of 1     s) with wavelength range set 
to  190 – 260   nm.  Th   e data were averaged and the spectrum of a sample-free control 
was subtracted. Secondary structural elements were calculated using the neural 
network program CDNN version 2.1 and the supplied neural network based on the 
33-member basis set  44 .   
  Docking procedure      .     Docking models of HSA and hFcRn were generated using the 
ZDOCK Fast Fourier Transform docking program  45 .  Th   e coordinates for HSA DIII 
(a.a. 382  –  582) were retrieved from the crystal structure of HSA at 2.5       Å   (PDB code 
1bm0)  20 .  Two  diff  erent models of hFcRn were used: the 2.7       Å   resolution structure 
of hFcRn at pH 8.2 (PDB code 1exu) and the 2.6       Å   resolution structure at pH 4.2 
(PDB code 3m17)  8,23 .  Th  e    β  2m domain was included in the docking. Th  e  ZDOCK 
program was run with preferences for docking poses with the two histidines, 
His-161 and His-166, in hFcRn, and residues His-464, His-510 and His-535 in 
HSA were part of the protein  –  protein interface. All crystal structure fi  gures were 
designed using   PyMOL   (  DeLano Scientifi   c  ) .                     
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